The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 356-361

  Gispert, Suzana ^a   Kurz, Alexander ^a   Waibel, Stefan ^b   Bauer, Peter ^c   Liepelt, Inga ^d   Geisen, Christof ^e   Gitler, Aaron D ^f   Becker, Tim ^g   Weber, Markus ^h   Berg, Daniela ^d   Andersen, Peter M ⁱ   Krüger, Rejko ^d   Riess, Olaf ^c   Ludolph, Albert C ^b   Auburger, Georg ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF BONN   (Germany)

^h Neuromuscular Diseases Unit/ALS Clinic   (Switzerland)

ⁱ UMEÅ UNIVERSITY   (Sweden)

Author keywords

Amyotrophic Lateral Sclerosis; Ataxin 2; Ataxin 3; Motor neuron disease; Parkinson's disease; RNA processing; Spinocerebellar Ataxia type 2

Indexed keywords

ATAXIN 2; POLYGLUTAMINE; REPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EUROPE; FAMILY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROMODULATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT;

ADULT; AGED; ALLELES; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PEPTIDES; REPRODUCIBILITY OF RESULTS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 81955162888     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.08.021     Document Type: Article

References (80)

1. Abahuni N., et al. Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease. Neurosci. Lett. 2007, 414:126-129.
2. Al-Ramahi I., et al. dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet. 2007, 3:e234.
3. Andersen P.M., et al. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph. Lateral Scler. 2007, 8:195-213.
4. Auburger G. Spinocerebellar Ataxia type 2, Chapter 26. Handbook of Clinical Neurology 2011, vol. 103. Elsevier Science. S.H. Subramony (Ed.).
5. Berg D., et al. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov. Disord. 2005, 20:1191-1194.
6. Berg D., et al. Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov. Disord. 2010, 25:1464-1469.
7. Burbulla L.F., et al. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum. Mol. Genet. 2010, 19:4437-4452.
8. Cancel G., et al. Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum. Mol. Genet. 1997, 6:709-715.
9. Charles P., et al. Are interrupted SCA2 CAG repeat expansions responsible for Parkinsonism?. Neurology 2007, 69:1970-1975.
10. Chen Y., et al. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 2011, 32(10):1925.e1-1925.e5.
11. Clark L.N., et al. Case-control study of the parkin gene in early-onset Parkinson disease. Arch. Neurol. 2006, 63:548-552.
12. Corrado L., et al. ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum. Genet. 2011, May 3 [Epub ahead of print].
13. D'Abreu A., et al. Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat. Disord. 2010, 16:2-7.
14. Daoud H., et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch. Neurol. 2011, 68:739-742.
15. Elden A.C., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466:1069-1075.
16. Fallon L., et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. 2006, 8:834-842.
17. Gibb W.R., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1988, 51:745-752.
18. Gispert S., et al. Failure to find alpha-synuclein gene dosage changes in 190 patients with familial Parkinson disease. Arch. Neurol. 2005, 62:96-98.
19. Gu W., et al. The shortest expanded allele of the MJD1 gene in a Chinese MJD kindred with autonomic dysfunction. Eur. Neurol. 2004, 52:107-111.
20. Gwinn-Hardy K., et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000, 55:800-805.
21. Gwinn-Hardy K., et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch. Neurol. 2001, 58:296-299.
22. Hallen L., et al. The KRAB-containing zinc-finger transcriptional regulator ZBRK1 activates SCA2 gene transcription through direct interaction with its gene product, ataxin-2. Hum. Mol. Genet. 2010, 20:104-114.
23. Huynh D.P., et al. Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Exp. Neurol. 2007, 203:531-541.
24. Imbert G., et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 1996, 14:285-291.
25. Infante J., et al. Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease. Mov. Disord. 2004, 19:848-852.
26. Infante J., et al. Autosomal dominant cerebellar ataxias in Spain: molecular and clinical correlations, prevalence estimation and survival analysis. Acta Neurol. Scand. 2005, 111:391-399.
27. Kim J.M., et al. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch. Neurol. 2007, 64:1510-1518.
28. Lagier-Tourenne C., Cleveland D.W. Neurodegeneration: an expansion in ALS genetics. Nature 2010, 466:1052-1053.
29. Lagier-Tourenne C., et al. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010, 19:R46-R64.
30. Landau W.M., et al. Hereditary spastic paraplegia and hereditary ataxia, Part 2: a family demonstrating various phenotypic manifestations with the SCA3 genotype. Arch. Neurol. 2000, 57:733-739.
31. Lastres-Becker I., et al. Spinocerebellar ataxia 2 (SCA2). Cerebellum 2008, 7:115-124.
32. Lavedan C., et al. Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease. DNA Res. 1998, 5:401-402.
33. Lee T., et al. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 2011, 76(24):2062-2065.
34. Lee T., et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum. Mol. Genet. 2011, 20(9):1697-1700.
35. Leroy E., et al. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395:451-452.
36. Lessing D., Bonini N.M. Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. PLoS Biol. 2008, 6:e29.
37. Levy D., et al. Genome-wide association study of blood pressure and hypertension. Nat. Genet. 2009, 41:677-687.
38. Li L.B., et al. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 2008, 453:1107-1111.
39. Liepelt I., et al. Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol. Aging 2009, 32(9):1599-1606.
40. Limprasert P., et al. Analysis of CAG repeat of the Machado-Joseph gene in human, chimpanzee and monkey populations: a variant nucleotide is associated with the number of CAG repeats. Hum. Mol. Genet. 1996, 5:207-213.
41. Lu C.S., et al. Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort. J. Neural Transm. Suppl. 2006, 235-240.
42. Maciel P., et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am. J. Hum. Genet. 1995, 57:54-61.
43. McCann C., et al. The Ataxin-2 protein is required for microRNA function and synapse-specific long-term olfactory habituation. Proc. Natl. Acad. Sci. U. S. A. 2011, Jul 27. [Epub ahead of print].
44. Munoz E., et al. Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease. J. Neurol. Sci. 2002, 200:19-25.
45. Newton-Cheh C., et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 2009, 41:666-676.
46. Nolte D., et al. Spinocerebellar ataxia type 17 associated with an expansion of 42 glutamine residues in TATA-box binding protein gene. J. Neurol. Neurosurg. Psychiatry 2010, 81:1396-1399.
47. Nonis D., et al. Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell. Signal. 2008, 20:1725-1739.
48. Orozco Diaz G., et al. Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguin, Cuba. Neurology 1990, 40:1369-1375.
49. Padiath Q.S., et al. Identification of a novel 45 repeat unstable allele associated with a disease phenotype at the MJD1/SCA3 locus. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 133B:124-126.
50. Payami H., et al. SCA2 may present as levodopa-responsive Parkinsonism. Mov. Disord. 2003, 18:425-429.
51. Pinto S., De Carvalho M. Machado-Joseph disease presenting as motor neuron disease. Amyotroph. Lateral Scler. 2008, 9:188-191.
52. Prestel J., et al. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov. Disord. 2006, 21:1763-1765.
53. Pulst S.M., et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 1996, 14:269-276.
54. Ralser M., et al. An integrative approach to gain insights into the cellular function of human ataxin-2. J. Mol. Biol. 2005, 346:203-214.
55. Ralser M., et al. Ataxin-2 and huntingtin interact with endophilin-A complexes to function in plastin-associated pathways. Hum. Mol. Genet. 2005, 14:2893-2909.
56. Restivo D.A., et al. Central motor conduction to lower limb after transcranial magnetic stimulation in spinocerebellar ataxia type 2 (SCA2). Clin. Neurophysiol. 2000, 111:630-635.
57. Rosa A.L., et al. Brisk deep-tendon reflexes as a distinctive phenotype in an Argentinean spinocerebellar ataxia type 2 pedigree. Mov. Disord. 2006, 21:66-68.
58. Ross O.A., et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum. Mol. Genet. 2011, 20(16):3207-3212.
59. Rubinsztein D.C., et al. Sequence variation and size ranges of CAG repeats in the Machado-Joseph disease, spinocerebellar ataxia type 1 and androgen receptor genes. Hum. Mol. Genet. 1995, 4:1585-1590.
60. Sanpei K., et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet. 1996, 14:277-284.
61. Satterfield T.F., Pallanck L.J. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum. Mol. Genet. 2006, 15:2523-2532.
62. Sebastiani P., et al. Genetic signatures of exceptional longevity in humans. Science 2010, 333(6041):404.
63. Seidel K., et al. Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol. 2010, 120:449-460.
64. Shan D.E., et al. Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann. Neurol. 2001, 50:812-815.
65. Shulman J.M., Feany M.B. Genetic modifiers of tauopathy in Drosophila. Genetics 2003, 165:1233-1242.
66. Sobczak K., Krzyzosiak W.J. CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts. J. Biol. Chem. 2005, 280:3898-3910.
67. Socal M.P., et al. Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. Parkinsonism Relat. Disord. 2009, 15:374-378.
68. Soraru G., et al. ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology 2011, 76:2030-2031.
69. Tain L.S., et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 2009, 12:1129-1135.
70. Tan C.F., et al. Selective occurrence of TDP-43-immunoreactive inclusions in the lower motor neurons in Machado-Joseph disease. Acta Neuropathol. 2009, 118:553-560.
71. Van Damme P., et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011, 76(24):2066-2072.
72. van de Loo S., et al. Ataxin-2 associates with rough endoplasmic reticulum. Exp. Neurol. 2009, 215:110-118.
73. Varrone A., et al. Reduced striatal [123 I]FP-CIT binding in SCA2 patients without parkinsonism. Ann. Neurol. 2004, 55:426-430.
74. Velazquez Perez L., et al. Molecular epidemiology of spinocerebellar ataxias in Cuba: insights into SCA2 founder effect in Holguin. Neurosci. Lett. 2009, 454:157-160.
75. Wang J.L., et al. Analysis of SCA2 and SCA3/MJD repeats in Parkinson's disease in mainland China: genetic, clinical, and positron emission tomography findings. Mov. Disord. 2009, 24:2007-2011.
76. Weber, M., in press. Familial ALS patients with SOD mutations in Switzerland show very diverse phenotypes and extreme long survival. J. Neurol. Neurosurg. Psychiatry. June 23. [Epub ahead of print].
77. Wiedemeyer R., et al. Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene 2003, 22:401-411.
78. Wilkins A., et al. SCA2 presenting as levodopa-responsive parkinsonism in a young patient from the United Kingdom: a case report. Mov. Disord. 2004, 19:593-595.
79. Yasuno K., et al. Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat. Genet. 2010, 42:420-425.
80. Yu Z., et al. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One 2011, 6:e17951.